Clinical review report Netupitant/palonosetron 300 mg/0.5 mg (Akynzeo) (Purdue Pharma)
The objective of the review was to identify, summarize, and critically assess the beneficial and harmful effects of Netupitant/palonosetron (NEPA) in preventing chemotherapy-induced nausea and vomiting (CINV) for patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemot...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820282506719 |
